The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.
Ignace B. Vergote
No relevant relationships to disclose
Florence Joly
No relevant relationships to disclose
Dionyssios Katsaros
No relevant relationships to disclose
Corneel Coens
No relevant relationships to disclose
Alexander Reinthaller
No relevant relationships to disclose
Marcia Hall
No relevant relationships to disclose
Christopher B. Steer
No relevant relationships to disclose
Nicoletta Colombo
No relevant relationships to disclose
Anne Lesoin
No relevant relationships to disclose
Antonio Casado
No relevant relationships to disclose
Edgar Petru
No relevant relationships to disclose
John Green
No relevant relationships to disclose
Martin Buck
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
No relevant relationships to disclose
Annamaria Ferrero
No relevant relationships to disclose
Laure Favier
No relevant relationships to disclose
Nicholas Reed
No relevant relationships to disclose
Herve Curve
No relevant relationships to disclose
Antonio Jimeno
No relevant relationships to disclose
Eric Pujade-Lauraine
No relevant relationships to disclose